Rescue therapy with mycophenolate mofetil

D. Conti, J. Baker, J. Wynn, M. Deierhoi, F. Stuart, E. Woodle, R. Ferguson, T. Gonwa, M. Pescovitz, C. Stiller, R. Mendez, J. Rosenthal, J. Pirsch, D. Cohen, J. Cerilli, C. Barker, R. Kauffman, J. Linna, S. Monroe, M. NavarroJ. Dunn, S. Inokuchi, S. Tomlanovich, R. Wilburn, J. Light

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Research with human transplant recipients has shown that mycophenolate mofetil (MMF) is a powerful and selective immunosuppressant for maintenance therapy following renal transplantation. An additional body of work suggests that it might also be a valuable tool for arresting ongoing rejection episodes. One randomized, open-label, multicenter study has compared the efficacy and safety of MMF administered with cyclosporine and maintenance corticosteroids versus high-dose intravenous corticosteroids (IV steroids) and conventional triple therapy, over a 6-month postenrollment period, for the treatment of refractory acute cellular renal allograft rejection. Treatment with MMF resulted in a 45% reduction in graft loss and death by 6 months postenrollment. (The number of deaths were the same in both treatment groups during the 6-month postenrollment period.) Treatment with MMF also significantly reduced the risk of experiencing a subsequent biopsy-proven rejection episode or treatment failure by almost 50%. The number of patients receiving one or more full courses of antilymphocyte therapy for a rejection episode subsequent to enrollment was more than twofold greater in the IV steroid group compared with the MMF group. Overall, and in most of the body systems, more adverse events were reported for patients in the MMF group, but the overall benefit-risk ratio for MMF supports its use with cyclosporine and maintenance corticosteroids for the treatment of refractory acute cellular renal allograft rejection.

Original languageEnglish (US)
Pages (from-to)131-135
Number of pages5
JournalClinical Transplantation
Volume10
Issue number1 II
StatePublished - Feb 1996
Externally publishedYes

Fingerprint

Mycophenolic Acid
Adrenal Cortex Hormones
Therapeutics
Cyclosporine
Allografts
Maintenance
Kidney
Immunosuppressive Agents
Treatment Failure
Kidney Transplantation
Multicenter Studies
Odds Ratio
Transplants
Biopsy
Safety

Keywords

  • Acute refractory rejection
  • Mycophenolate mofetil
  • Renal allograft
  • Rescue therapy

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Conti, D., Baker, J., Wynn, J., Deierhoi, M., Stuart, F., Woodle, E., ... Light, J. (1996). Rescue therapy with mycophenolate mofetil. Clinical Transplantation, 10(1 II), 131-135.

Rescue therapy with mycophenolate mofetil. / Conti, D.; Baker, J.; Wynn, J.; Deierhoi, M.; Stuart, F.; Woodle, E.; Ferguson, R.; Gonwa, T.; Pescovitz, M.; Stiller, C.; Mendez, R.; Rosenthal, J.; Pirsch, J.; Cohen, D.; Cerilli, J.; Barker, C.; Kauffman, R.; Linna, J.; Monroe, S.; Navarro, M.; Dunn, J.; Inokuchi, S.; Tomlanovich, S.; Wilburn, R.; Light, J.

In: Clinical Transplantation, Vol. 10, No. 1 II, 02.1996, p. 131-135.

Research output: Contribution to journalArticle

Conti, D, Baker, J, Wynn, J, Deierhoi, M, Stuart, F, Woodle, E, Ferguson, R, Gonwa, T, Pescovitz, M, Stiller, C, Mendez, R, Rosenthal, J, Pirsch, J, Cohen, D, Cerilli, J, Barker, C, Kauffman, R, Linna, J, Monroe, S, Navarro, M, Dunn, J, Inokuchi, S, Tomlanovich, S, Wilburn, R & Light, J 1996, 'Rescue therapy with mycophenolate mofetil', Clinical Transplantation, vol. 10, no. 1 II, pp. 131-135.
Conti D, Baker J, Wynn J, Deierhoi M, Stuart F, Woodle E et al. Rescue therapy with mycophenolate mofetil. Clinical Transplantation. 1996 Feb;10(1 II):131-135.
Conti, D. ; Baker, J. ; Wynn, J. ; Deierhoi, M. ; Stuart, F. ; Woodle, E. ; Ferguson, R. ; Gonwa, T. ; Pescovitz, M. ; Stiller, C. ; Mendez, R. ; Rosenthal, J. ; Pirsch, J. ; Cohen, D. ; Cerilli, J. ; Barker, C. ; Kauffman, R. ; Linna, J. ; Monroe, S. ; Navarro, M. ; Dunn, J. ; Inokuchi, S. ; Tomlanovich, S. ; Wilburn, R. ; Light, J. / Rescue therapy with mycophenolate mofetil. In: Clinical Transplantation. 1996 ; Vol. 10, No. 1 II. pp. 131-135.
@article{8603f547256c41c8aa94f44b05488ecf,
title = "Rescue therapy with mycophenolate mofetil",
abstract = "Research with human transplant recipients has shown that mycophenolate mofetil (MMF) is a powerful and selective immunosuppressant for maintenance therapy following renal transplantation. An additional body of work suggests that it might also be a valuable tool for arresting ongoing rejection episodes. One randomized, open-label, multicenter study has compared the efficacy and safety of MMF administered with cyclosporine and maintenance corticosteroids versus high-dose intravenous corticosteroids (IV steroids) and conventional triple therapy, over a 6-month postenrollment period, for the treatment of refractory acute cellular renal allograft rejection. Treatment with MMF resulted in a 45{\%} reduction in graft loss and death by 6 months postenrollment. (The number of deaths were the same in both treatment groups during the 6-month postenrollment period.) Treatment with MMF also significantly reduced the risk of experiencing a subsequent biopsy-proven rejection episode or treatment failure by almost 50{\%}. The number of patients receiving one or more full courses of antilymphocyte therapy for a rejection episode subsequent to enrollment was more than twofold greater in the IV steroid group compared with the MMF group. Overall, and in most of the body systems, more adverse events were reported for patients in the MMF group, but the overall benefit-risk ratio for MMF supports its use with cyclosporine and maintenance corticosteroids for the treatment of refractory acute cellular renal allograft rejection.",
keywords = "Acute refractory rejection, Mycophenolate mofetil, Renal allograft, Rescue therapy",
author = "D. Conti and J. Baker and J. Wynn and M. Deierhoi and F. Stuart and E. Woodle and R. Ferguson and T. Gonwa and M. Pescovitz and C. Stiller and R. Mendez and J. Rosenthal and J. Pirsch and D. Cohen and J. Cerilli and C. Barker and R. Kauffman and J. Linna and S. Monroe and M. Navarro and J. Dunn and S. Inokuchi and S. Tomlanovich and R. Wilburn and J. Light",
year = "1996",
month = "2",
language = "English (US)",
volume = "10",
pages = "131--135",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "1 II",

}

TY - JOUR

T1 - Rescue therapy with mycophenolate mofetil

AU - Conti, D.

AU - Baker, J.

AU - Wynn, J.

AU - Deierhoi, M.

AU - Stuart, F.

AU - Woodle, E.

AU - Ferguson, R.

AU - Gonwa, T.

AU - Pescovitz, M.

AU - Stiller, C.

AU - Mendez, R.

AU - Rosenthal, J.

AU - Pirsch, J.

AU - Cohen, D.

AU - Cerilli, J.

AU - Barker, C.

AU - Kauffman, R.

AU - Linna, J.

AU - Monroe, S.

AU - Navarro, M.

AU - Dunn, J.

AU - Inokuchi, S.

AU - Tomlanovich, S.

AU - Wilburn, R.

AU - Light, J.

PY - 1996/2

Y1 - 1996/2

N2 - Research with human transplant recipients has shown that mycophenolate mofetil (MMF) is a powerful and selective immunosuppressant for maintenance therapy following renal transplantation. An additional body of work suggests that it might also be a valuable tool for arresting ongoing rejection episodes. One randomized, open-label, multicenter study has compared the efficacy and safety of MMF administered with cyclosporine and maintenance corticosteroids versus high-dose intravenous corticosteroids (IV steroids) and conventional triple therapy, over a 6-month postenrollment period, for the treatment of refractory acute cellular renal allograft rejection. Treatment with MMF resulted in a 45% reduction in graft loss and death by 6 months postenrollment. (The number of deaths were the same in both treatment groups during the 6-month postenrollment period.) Treatment with MMF also significantly reduced the risk of experiencing a subsequent biopsy-proven rejection episode or treatment failure by almost 50%. The number of patients receiving one or more full courses of antilymphocyte therapy for a rejection episode subsequent to enrollment was more than twofold greater in the IV steroid group compared with the MMF group. Overall, and in most of the body systems, more adverse events were reported for patients in the MMF group, but the overall benefit-risk ratio for MMF supports its use with cyclosporine and maintenance corticosteroids for the treatment of refractory acute cellular renal allograft rejection.

AB - Research with human transplant recipients has shown that mycophenolate mofetil (MMF) is a powerful and selective immunosuppressant for maintenance therapy following renal transplantation. An additional body of work suggests that it might also be a valuable tool for arresting ongoing rejection episodes. One randomized, open-label, multicenter study has compared the efficacy and safety of MMF administered with cyclosporine and maintenance corticosteroids versus high-dose intravenous corticosteroids (IV steroids) and conventional triple therapy, over a 6-month postenrollment period, for the treatment of refractory acute cellular renal allograft rejection. Treatment with MMF resulted in a 45% reduction in graft loss and death by 6 months postenrollment. (The number of deaths were the same in both treatment groups during the 6-month postenrollment period.) Treatment with MMF also significantly reduced the risk of experiencing a subsequent biopsy-proven rejection episode or treatment failure by almost 50%. The number of patients receiving one or more full courses of antilymphocyte therapy for a rejection episode subsequent to enrollment was more than twofold greater in the IV steroid group compared with the MMF group. Overall, and in most of the body systems, more adverse events were reported for patients in the MMF group, but the overall benefit-risk ratio for MMF supports its use with cyclosporine and maintenance corticosteroids for the treatment of refractory acute cellular renal allograft rejection.

KW - Acute refractory rejection

KW - Mycophenolate mofetil

KW - Renal allograft

KW - Rescue therapy

UR - http://www.scopus.com/inward/record.url?scp=0013481829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0013481829&partnerID=8YFLogxK

M3 - Article

C2 - 8680050

AN - SCOPUS:0013481829

VL - 10

SP - 131

EP - 135

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 1 II

ER -